Flobufen

Flobufen (VUFB 16066) is a non-steroidal anti-inflammatory agent and cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) inhibitor agent. Flobufen inhibits alloantigen-driven cellular immune responses and stimulates phagocytosis of peritoneal cells. Flobufen can improve immunopathological disorders and has an inhibitory effect on rheumatoid arthritis[1][2][3].

Product Specifications

CAS Number

[112344-52-2]

Product Name Alternative

VUFB 16066

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

COX; Lipoxygenase

Type

Reference compound

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/flobufen.html

Purity

98.85

Solubility

DMSO : 40 mg/mL (ultrasonic;adjust pH to 9 with 1 M NaOH)

Smiles

FC1=C(C2=CC=C(C(CC(C)C(O)=O)=O)C=C2)C=CC(F)=C1

Molecular Formula

C17H14F2O3

Molecular Weight

304.29

Precautions

H302, H315, H319, H335

References & Citations

[1]Kvasnicková E, et al. Metabolic pathways of flobufen-a new antirheumatic and antiarthritic drug. Interspecies comparison. Exp Toxicol Pathol. 1999 Jul;51 (4-5) :352-6.|[2]Drsata J, et al. Inhibice dekarboxylázy aromatických aminokyselin protizánĕtlivými látkami flobufenem a kyselinou 2',4'-difluorbifenyl-4-yloctovou [Inhibition of aromatic amino acid decarboxylases by the anti-inflammatory agent flobufen and 2',4'-difluorbiphenyl-4-acetic acid]. Cesk Farm. 1989 Nov;38 (9) :407-10.|[3]Panajotova V, et al. Pharmacological profile of the novel potent antirheumatic 4- (2',4'-difluorobiphenyl-4-yl) -2-methyl-4-oxobutanoic acid. Arzneimittelforschung.